



## Therapeutic Targets in Chronic Lymphocytic Leukemia

Guest Editors:

**Dr. Luca Laurenti**

Institute of Hematology,  
Università Cattolica del Sacro  
Cuore, Rome, Italy

**Dr. Dimitar Efremov**

International Centre for Genetic  
Engineering and Biotechnology,  
Trieste, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2022)**

### Message from the Guest Editors

Dear Colleagues,

In recent years, major progress has been made in understanding the cellular and molecular mechanisms that drive chronic lymphocytic leukemia. This knowledge has resulted in the development of novel drugs that have revolutionized treatment of this disease. Among these, drugs that target the B cell receptor pathway and the antiapoptotic protein BCL2 have already been successfully exploited in the clinic and have become available for routine clinical use. However, although most patients initially respond to treatment with these drugs, the vast majority achieve only a partial remission, and a substantial proportion of these subsequently suffer a relapse or undergo Richter transformation, for which no effective treatment currently exists. To further improve treatment responses, combinations of drugs that target patient-specific genetic lesions and common microenvironmental signals will most likely be required.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI